BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 2889299)

  • 41. [Peptic ulcer: new aspects of conservative therapy].
    Bernoulli R
    Schweiz Med Wochenschr; 1977 May; 107(18):618-22. PubMed ID: 17157
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Omeprazole: a pharmacoeconomic evaluation of its use in duodenal ulcer and reflux oesophagitis.
    Barradell LB; McTavish D
    Pharmacoeconomics; 1993 Jun; 3(6):482-510. PubMed ID: 10146883
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Omeprazole and maintenance treatment: new concepts for traditional therapies?].
    Díaz de Rojas F; Ponce García J
    An Med Interna; 1992 Sep; 9(9):450-4. PubMed ID: 1391583
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Treatment of acid-peptic diseases by inhibition of gastric H+,K+-ATPase.
    McArthur KE; Jensen RT; Gardner JD
    Annu Rev Med; 1986; 37():97-105. PubMed ID: 3010811
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The clinical safety of omeprazole.
    Sölvell L
    Scand J Gastroenterol Suppl; 1989; 166():106-10; discussion 111-3. PubMed ID: 2690327
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Therapy and prevention of duodenal and gastric ulcer with histamine-H2-receptor antagonists].
    Hentschel E
    Wien Med Wochenschr; 1983; 133(4-5):104-7. PubMed ID: 6134397
    [No Abstract]   [Full Text] [Related]  

  • 47. Effect of omeprazole, a substituted benzimidazole, on 24-h intragastric acidity in patients with peptic ulcer disease.
    Naesdal J; Bodemar G; Walan A
    Scand J Gastroenterol; 1984 Oct; 19(7):916-22. PubMed ID: 6531660
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Refractory peptic ulcers.
    Arakawa T; Kobayashi K; Dajani EZ
    J Assoc Acad Minor Phys; 1992; 3(3):95-102. PubMed ID: 1386767
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Controversies, dilemmas, and dialogues. Reduction of gastric acidity in the treatment of peptic ulcer disease: how low should we go?
    Peterson WL; Harford WV
    Am J Gastroenterol; 1991 Jun; 86(6):671-5. PubMed ID: 1674838
    [No Abstract]   [Full Text] [Related]  

  • 50. Recent advances in the management of gastric acid hypersecretion in patients with Zollinger-Ellison syndrome.
    Maton PN; Gardner JD; Jensen RT
    Gastroenterol Clin North Am; 1989 Dec; 18(4):847-63. PubMed ID: 2575602
    [TBL] [Abstract][Full Text] [Related]  

  • 51. H2 receptor antagonists.
    Siepler JK; Campagna KD; Donahue PE; Bombeck CT
    Am J Hosp Pharm; 1978 Feb; 35(2):141-5. PubMed ID: 24338
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Treatment of patients with Zollinger-Ellison syndrome.
    Mignon M; Pospai D; Forestier S; Vatier J; Vallot T
    Clin Ther; 1993; 15 Suppl B():22-31. PubMed ID: 8205592
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Review of peptic ulcer maintenance trials.
    Robinson M
    Am J Med; 1984 Nov; 77(5B):23-9. PubMed ID: 6095657
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Omeprazole. A new substance for inhibiting acid production].
    Uhl D
    Med Monatsschr Pharm; 1990 Feb; 13(2):34-7. PubMed ID: 2179691
    [No Abstract]   [Full Text] [Related]  

  • 55. Meta-analysis of randomized clinical trials comparing lansoprazole with ranitidine or famotidine in the treatment of acute duodenal ulcer.
    Poynard T; Lemaire M; Agostini H
    Eur J Gastroenterol Hepatol; 1995 Jul; 7(7):661-5. PubMed ID: 8590162
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Can optimal acid suppression prevent rebleeding in peptic ulcer patients with a non-bleeding visible vessel: a preliminary report of a randomized comparative study.
    Lin HJ; Lo WC; Perng CL; Wang K; Lee FY
    Hepatogastroenterology; 1997; 44(17):1495-9. PubMed ID: 9356879
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Omeprazole versus ranitidine or ranitidine/metoclopramide in poorly responsive symptomatic gastroesophageal reflux disease.
    Richter JE; Sabesin SM; Kogut DG; Kerr RM; Wruble LD; Collen MJ
    Am J Gastroenterol; 1996 Sep; 91(9):1766-72. PubMed ID: 8792695
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Famotidine. Pharmacodynamic and pharmacokinetic properties and a preliminary review of its therapeutic use in peptic ulcer disease and Zollinger-Ellison syndrome.
    Campoli-Richards DM; Clissold SP
    Drugs; 1986 Sep; 32(3):197-221. PubMed ID: 2875864
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clinical development programme for omeprazole.
    Walan A
    Digestion; 1990; 47 Suppl 1():54-8; discussion 76. PubMed ID: 2093016
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Omeprazole vs. ranitidine in the short-term treatment of duodenal ulcer: an Italian multicenter study.
    Barbara L; Blasi A; Cheli R; Corinaldesi R; Dobrilla G; Francavilla A; Rinetti M; Vezzaldini P; Abbiati R; Gradnik R
    Hepatogastroenterology; 1987 Oct; 34(5):229-32. PubMed ID: 3315923
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.